Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year Low – Here’s Why

Kailera Therapeutics, Inc. (NASDAQ:KLRA) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $16.37 and last traded at $16.56, with a volume of 39516 shares trading hands. The stock had previously closed at $17.17.

Analyst Ratings Changes

A number of research firms have recently weighed in on KLRA. Jefferies Financial Group began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $48.00 target price for the company. William Blair began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating for the company. Weiss Ratings started coverage on shares of Kailera Therapeutics in a research report on Friday, August 14th. They issued a “sell (d)” rating on the stock. TD Cowen initiated coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $57.00 target price for the company. Finally, Evercore initiated coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.75.

Kailera Therapeutics Stock Performance

The firm’s 50 day moving average price is $19.28. The company has a market capitalization of $2.17 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). As a group, equities analysts expect that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Kailera Therapeutics in the 2nd quarter worth approximately $113,923,000. Wellington Management Group LLP bought a new stake in Kailera Therapeutics in the second quarter worth $64,308,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Kailera Therapeutics in the second quarter worth $24,233,000. Finally, California State Teachers Retirement System purchased a new stake in shares of Kailera Therapeutics in the second quarter worth $309,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.